Clinical Trials

219 enrolled 32 charts 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03513952 2024-07-26

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

47 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03397394 2023-06-09

ATLAS

97 enrolled 12 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

2 enrolled 8 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

8 enrolled 16 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00478361 2020-10-09

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

40 enrolled 7 charts

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00749892 2020-09-10

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

34 enrolled 9 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02178241 2019-12-16

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

26 enrolled 9 charts

Ureteral Neoplasms, Urethral Neoplasms

NCT01282463 2019-09-09

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

148 enrolled 19 charts

Carcinoma, Renal Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

142 enrolled 13 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

NCT00022633 2016-08-11

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

65 enrolled 14 charts

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00397488 2016-01-25

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium

78 enrolled 6 charts

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00407485 2014-10-20

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

22 enrolled 7 charts

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00112905 2014-05-30

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

27 enrolled 8 charts

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00471536 2014-05-30

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

19 enrolled 8 charts

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00045630 2013-05-27

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

77 enrolled 11 charts

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00661609 2011-01-12

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

54 enrolled 10 charts